Viridian Therapeutics, Inc.

NASDAQ:VRDN

Biotechnology

Healthcare
$31.44 -0.88%

-$0.15 today

Market cap
$3.57B
Beta
0.90
P/E (TTM)
-4.7
EPS (TTM)
-$3.53
52W Low $13.18High $34.29

Volume 4.02M

Average 2.86M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$276.39M

FY 2025 · Annual

Investing Cash Flow

-$37.56M

FY 2025 · Annual

Financing Cash Flow

$426.74M

FY 2025 · Annual

-6.8% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(79.41M)(129.87M)(237.73M)(269.95M)(342.6M)
Depreciation & Amortization120K255K522K540K460K
Deferred Income Tax00000
Stock-Based Compensation14.47M19.77M67.17M42.15M44.3M
Change in Working Capital1.72M15.96M(9.43M)9.6M23.03M
Accounts Receivables(451K)349K0102K0
Inventory00000
Accounts Payables1.66M11.52M(12.04M)(73K)6.56M
Other Working Capital520K4.09M2.62M9.57M16.47M
Other Non-Cash Items8.52M54K(4.71M)(14.66M)(1.58M)
Operating Cash Flow(54.58M)(93.84M)(184.17M)(232.32M)(276.39M)
Capital Expenditures(338K)(797K)(898K)(511K)(495K)
Acquisitions (Net)00000
Purchases of Investments(188.43M)(223.26M)(407.88M)(695.07M)(579.28M)
Sales of Investments114.4M108.94M314.53M466.93M542.21M
Other Investing Activities79K0000
Investing Cash Flow(74.29M)(115.13M)(94.25M)(228.65M)(37.56M)
Debt Repayment05M15M028.88M
Common Stock Issued114.24M291.87M125.07M453.66M348.33M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(5.93M)(18.63M)9.41M(20.92M)49.54M
Financing Cash Flow125.28M322.24M225.67M457.74M426.74M
Effect of Forex Changes00000
Net Change in Cash(3.6M)113.28M(52.75M)(3.23M)112.79M
Free Cash Flow(54.92M)(94.64M)(185.07M)(232.83M)(276.89M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$342.6M
+ D&A$460.0K
+ Stock-Based Comp$44.3M
+ Deferred Tax$0
+ Working Capital$23.0M
- Other Non-Cash-$1.6M
= Operating Cash Flow-$276.4M
- Capex-$495.0K
= Free Cash Flow-$276.9M

Analysis

FY2025 free cash flow is -$276.9M. FCF conversion is 80.8% of net income. Operating cash flow was -$276.4M, with capex of -$495.0K. The largest bridge item is Stock-Based Comp at $44.3M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 10, 2026
8-KCurrent reportNov 9, 2026
8-KCurrent reportNov 4, 2026
10-QQuarterly reportNov 4, 2026
4Statement of changes in beneficial ownershipAug 20, 2026

Does VRDN generate free cash flow?

Viridian Therapeutics, Inc. (VRDN) generated -$276.89M of free cash flow in fiscal 2025.

How much operating cash flow does VRDN produce?

Operating cash flow was -$276.39M, before capital expenditures of $495,000.00.